Phase 2b Study Evaluates KT-621 for Eosinophilic Asthma

This Phase 2b study, sponsored by Kymera Therapeutics, Inc., is currently recruiting participants to evaluate the safety and efficacy of KT-621, an investigational oral drug, in adults with uncontrolled moderate to severe eosinophilic asthma. The study aims to enroll an estimated 264 participants and will measure the primary outcome of change from baseline in pre-bronchodilator FEV1. The trial will also assess the safety, tolerability, and pharmacokinetics of KT-621. The study began on January 28, 2026, with a primary completion date projected for December 2027. As this is an ongoing study, results regarding the efficacy and safety of KT-621 are not yet available.

If you or someone you know suffers from uncontrolled moderate to severe eosinophilic asthma, there's a new treatment being tested called KT-621. This Phase 2b study is designed to see how well KT-621 works and how safe it is for patients. Eosinophilic asthma is a type of asthma that can be particularly difficult to manage, and finding effective treatments is crucial for improving quality of life. The study will measure how KT-621 affects lung function, specifically looking at a measurement called FEV1, which indicates how much air you can forcefully exhale in one second. With 264 participants expected to enroll, this research could provide valuable insights into a new option for those who struggle to control their asthma symptoms. If successful, KT-621 might offer hope for better management of this challenging condition.